A5045902068- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Liver Disease Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pain Management and Opioid Use
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Pharmacological Effects and Toxicity Studies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Liver Disease and Transplantation
- Ferroptosis and cancer prognosis
- Microtubule and mitosis dynamics
- Genetic factors in colorectal cancer
- Radiomics and Machine Learning in Medical Imaging
National Taiwan University
2016-2025
National Taiwan University Hospital
2016-2025
Nanjing University of Science and Technology
2024
Nanjing Medical University
2017-2024
Hainan Maternal and Child Health Hospital
2024
National Taipei University
2014-2023
Jiangsu Province Hospital
2017-2023
First Affiliated Hospital of Bengbu Medical College
2021
Shanghai Sixth People's Hospital
2021
Shanghai Jiao Tong University
2021
Abstract BACKGROUND: Antiangiogenic therapy has become the most important treatment modality for patients with advanced hepatocellular carcinoma (HCC). In this study, authors investigated levels of alpha‐fetoprotein (AFP) as a potential biomarker efficacy antiangiogenic therapy. METHODS: Patients HCC who had been enrolled in 3 prospective phase 2 clinical trials that evaluated either sorafenib, bevacizumab, or thalidomide combination potentially antiangiogenic, metronomic, oral...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society had established management consensus guideline 2016. current recommendations focus on updating critical issues regarding HCC, including surveillance, diagnosis, systemic treatment. For updated suggests role dynamic computed tomography or magnetic resonance imaging contrast-enhanced ultrasound (CEUS) selected patients. this update...
The TGF-β signaling pathway is crucial in the progression and metastasis of malignancies. We investigated whether serum TGF-β1 level was related to outcomes patients treated with sorafenib for advanced hepatocellular carcinoma (HCC).We selected who had received sorafenib-containing regimens as first-line therapy HCC between 2007 2012. Serum levels were measured correlated treatment outcomes. expression sensitivity examined cell lines.Ninety-one included; 62 (68%) hepatitis B virus surface...
Abstract Background Post‐treatment decline in serum alpha‐foetoprotein (AFP) levels has been shown to predict the treatment efficacy of antiangiogenic therapy for advanced hepatocellular carcinoma (HCC). We explored whether a AFP was also associated with outcomes immune checkpoint inhibitors (ICIs) patients HCC. Methods reviewed all who received ICI response evaluated pretreatment level >20 ng/mL. defined early as >20% within first 4 weeks initiation relative levels. then studied...
Immune checkpoint inhibitors (ICIs) exhibit significant clinical activity in patients with advanced hepatocellular carcinoma (HCC). This study explored whether tumor response to ICIs HCC varies among different organs.We reviewed the data of who had received ICIs. Patients measurable diseases were enrolled. Organ-specific criteria, adapted from RECIST 1.1 and immune-related RECIST, used evaluate objective tumors located liver, lung, lymph node, other intra-abdominal sites.Of 75 enrolled HCC,...
Sorafenib has become the standard therapy for patients with advanced hepatocellular carcinoma (HCC). Unfortunately, most eventually develop acquired resistance. Therefore, it is important to identify potential biomarkers that could predict efficacy of sorafenib. To target proteins associated development sorafenib resistance, we applied stable isotope labelling amino acids in cell culture (SILAC)-based quantitative proteomic approach analyze differences protein expression levels between...
Programmed death-ligand 1 (PD-L1) expression in the tumor microenvironment (TME) has been reported to be related prognosis patients with hepatocellular carcinoma (HCC) after hepatectomy. The impact of sorafenib on PD-L1 TME advanced HCC is unclear.Patients who received for disease at National Taiwan University Hospital, Taipei, Taiwan, and had paired tissues obtained before treatment were included study group. not treated primary recurrent or metastatic identified as reference membrane...
Previous studies have shown left-sided colorectal cancer (LCRC) and right-sided (RCRC) exhibit different molecular clinicopathological features. We explored the association between primary tumor site cetuximab efficacy in KRAS wild-type (CRC). This study enrolled a cohort of patients, who had received treatment after two or more lines chemotherapy for (exon 2 nonmutant) metastatic CRC, from databases Taiwan Cancer Registry (2004–2010) National Health Insurance (2004–2011). Survival data were...
This study explored the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and use antibiotics in advanced esophageal squamous cell carcinoma (ESCC) patients receiving immune checkpoint inhibitors (ICIs).Patients were enrolled from two referral centers Taiwan. Clinical benefit was defined as complete response, partial or a stable disease for ≥6 months via Response Evaluation Criteria In Solid Tumors 1.1. Clinicopathological factors' impact on overall survival (OS)...
600 Background: Immunotherapy combinations such as atezolizumab plus bevacizumab (Atezo-Bev) or STRIDE have been established standard therapies for patients with advanced hepatocellular carcinoma (HCC). After dual immunotherapy treatment, durable responders and long-term survivors had reported. However, the longevity of outcomes following Atezo-Bev treatment remains to be evaluated. Methods: We analyzed medical records four centers in Taiwan Child-Pugh class A liver reserve who received...
568 Background: Chronic hepatitis B virus (HBV) infection is a common etiology of HCC, especially in East Asia. Clinical trials using immune checkpoint inhibitors (ICIs) usually exclude patients with chronic active (serum HBV viral load > 2000 IU/mL) or require the to be below certain level anti-HBV medications. This study examines safety and efficacy concurrently administering STRIDE regimen (durvalumab single dose tremelimumab) durvalumab alone medications this patient population....
Immunotherapy targeting the programmed death-ligand 1 (PD-L1) pathway is a standard treatment for advanced hepatocellular carcinoma (HCC). The Wnt signaling pathway, often upregulated in HCC, contributes to an immunosuppressive tumor microenvironment. This study investigated impact of inhibition on PD-L1 expression HCC and evaluated potential therapeutic benefit combining with blockade. effects inhibitors XAV939 IWR-1 were examined human cell lines HuH7 Hep3B. Beta-catenin overexpression...
<b><i>Objectives:</i></b> The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. This multicenter across several Asian countries to evaluate safety and efficacy of this population. <b><i>Methods:</i></b> Patients histology-proven HCC, disease Child-Pugh class A liver function received bevacizumab 5 mg/kg intravenously every 2 weeks...
Antiangiogenic therapy is crucial for advanced hepatocellular carcinoma (HCC) treatment. Interleukin (IL)-6 an inflammatory response mediator that can promote angiogenesis. We explored its prognostic role in patients with HCC.We had two patient cohorts, both comprising who received sorafenib-containing as the first-line treatment HCC. best cut point pretreatment plasma IL-6 levels exploration cohort and then confirmed it validation cohort.In total, 55 73 constituted respectively. In cohort,...